GlassScriptPhysician profile
Samuel Rice Baxter
NPI 1902292360
$10,864.54
in general payments reported to CMS, 2019-2025
11 companies · $2,348 in 2025
The $2,348 reported for 2025 was more than what a typical Adult Reconstructive Orthopaedic Surgery provider received nationally (typical 2025 total: $1,425).
See the full distribution for Adult Reconstructive Orthopaedic Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.12 · 2021: $2,565 · 2022: $3,178 · 2023: $1,569 · 2024: $1,175 · 2025: $2,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,883 · Food and Beverage: $1,710 · Consulting Fee: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,882.51 |
| Food and Beverage | $1,710.22 |
| Consulting Fee | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medacta USA, INC. | $8,122.48 | 2021-2025 | Gmk Sphere, Spherika, M-Vizion |
| Zimmer Biomet Holdings, INC. | $1,833.02 | 2022-2025 | Arcos, Rosa, Persona |
| Stryker Corporation | $308.53 | 2020-2025 | Mako, X3 |
| Molnlycke Health Care US, LLC | $223.64 | 2022 | |
| Next Science LLC | $116.30 | 2024 | Xperience, Blastx, Surgx |
| Vertex Pharmaceuticals Incorporated | $71.53 | 2025 | |
| Depuy Synthes Sales INC. | $45.42 | 2021-2025 | Orthovisc, Monovisc |
| Innovation Technologies INC | $45.21 | 2024-2025 | Irrisept |
| Heron Therapeutics, INC. | $43.73 | 2024 | Zynrelef |
| Bioventus LLC | $32.30 | 2022-2025 | Durolane |
| Ferring Pharmaceuticals INC. | $22.38 | 2025 | Euflexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.